Genelux (GNLX) Shares Outstanding (Diluted Average) (2022 - 2026)
Genelux (GNLX) recorded quarterly Shares Outstanding (Diluted Average) of $44.2 million in Q1 2026, up 18.76% quarter-over-quarter from $37.2 million in Q4 2025, and up 26.41% on a YoY basis from $34.9 million in Q1 2025.
Genelux (GNLX) Shares Outstanding (Diluted Average) (2022 - 2026) Analysis & Trends
Genelux's Shares Outstanding (Diluted Average) history runs 5 years deep, the most recent figure standing at $44.2 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 26.41% year-over-year to $44.2 million; the TTM figure through Mar 2026 stood at $44.2 million (up 26.41% YoY), while the FY2025 annual figure was $37.2 million, up 18.21% from the prior year.
- Shares Outstanding (Diluted Average) was $44.2 million for Q1 2026 at Genelux, up from $37.2 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $44.2 million in Q1 2026 to a low of $9.1 million in Q4 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $28.2 million across 5 years, with a median of $28.3 million in 2024.
- The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Diluted Average) soared 167.97% in 2023, then gained 6.76% in 2025.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $9.1 million in 2022, then soared by 167.97% to $24.4 million in 2023, then advanced by 28.74% to $31.5 million in 2024, then climbed by 18.21% to $37.2 million in 2025, then rose by 18.76% to $44.2 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $44.2 million (Q1 2026), $37.2 million (Q4 2025), and $36.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | 44.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.15 Mn |
| Dec 31, 2025 | 37.18 Mn |
| Sep 30, 2025 | 36.87 Mn |
| Jun 30, 2025 | 36.35 Mn |
| Mar 31, 2025 | 34.93 Mn |
| Dec 31, 2024 | 31.45 Mn |
| Sep 30, 2024 | 34.53 Mn |
| Jun 30, 2024 | 28.31 Mn |
| Mar 31, 2024 | 26.85 Mn |
| Dec 31, 2023 | 24.43 Mn |
| Sep 30, 2023 | 23.64 Mn |
| Jun 30, 2023 | 25.07 Mn |
| Mar 31, 2023 | 19.58 Mn |
| Dec 31, 2022 | 9.12 Mn |
| Sep 30, 2022 | 10.07 Mn |